Overview

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
0
Participant gender:
All
Summary
Epidermal Growth Factor Receptor tyrosine-kinase inhibitors (EGFR-TKIs), including gefitinib,erlotinib and icotinib demonstrate excellent effect on the treatment of non small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. In this study, the investigators aim to explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
China Medical University, China
Collaborators:
General Hospital of Shenyang Military Region
Liaoning Tumor Hospital & Institute
Shengjing Hospital
The First Affiliated Hospital of Dalian Medical University
The Second Affiliated Hospital of Dalian Medical University
Treatments:
Erlotinib Hydrochloride
Gefitinib
Criteria
Inclusion Criteria:

1. Obtain of informed consent.

2. Histologically or cytologically confirmed, inoperable, recurrence or metastasis
advanced non-small cell lung cancer (TNM Stage ⅢB or stage Ⅳ), took EGFR-TKI longer
than 6 months and appeared disease progression.

3. At least one measurable lesion (helical CT scan long diameter ≥10mm, meet the
requirements of the standard Response Evaluation Criteria In Solid Tumors(RESCIST)
version 1.1).

4. Eastern Cooperative Oncology Group(ECOG)Performance Status(PS) :0-2.

5. Aged from 18 to 75 years (18 and 75 years are included).

6. Life expectancy ≥12 weeks.

7. Adequate bone marrow reserve and organ function as follows:

Absolute neutrophils count (ANC) ≥1.5 x 10 to the 9th power/L (band neutrophil and
segmented neutrophil), platelets > 100 x 10 to the 9th power/L and Hb≥90g/L.

Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN).

Alkaline phosphatase (AP), alanine transaminase (ALT) and aspartate transaminase (AST)
less than or equal to 3.0 times ULN (or less than or equal to 5 times ULN in case of
known liver involvement.

Renal: Serum Creatinine less than or equal to 1.25 times upper limit of normal (ULN).

8. Females of child-bearing potential must have negative serum pregnancy test. Sexually
active males and females (of childbearing potential) willing to practice contraception
during the study.

Exclusion Criteria:

1. Do not meet the above criteria.

2. Unhealed toxicity of prior anti-cancer treatment (CTCAE Level 1) or surgery.

3. Symptomatic Central Nervous System (CNS) metastases.

4. Clinical uncontrolled active infection, such as acute pneumonia, active hepatitis B or
C (prior hepatitis B history, despite medication treatment control or not, HBV
DNA≥500copies or ≥100IU/ml), etc.

5. Prior other malignant disease in 5 years (except carcinoma in situ of cervix, or non
melanoma skin cancers, or localized prostate cancer with Gleason ≤6).

6. Take part in new drug clinical trials within one month or taking part in a trial now.

7. Pregnant or lactating woman.

8. Other conditions regimented at investigators' discretion.